Skip to main content
Premium Trial:

Request an Annual Quote

Roche: Andreas Oeri, John Bell

Roche announced Andreas Oeri will retire from the company's board of directors in 2020, to be replaced by Jörg Duschmalé. Oeri was previously chairman of the company's corporate governance and sustainability committee. Also, the company said that John Bell will not stand for reelection to the board in 2020, and the board has proposed Patrick Frost, CEO of the Swiss Life Group, for his replacement. 

Additionally, Gottlieb Keller, Roche's general counsel, a member of the corporate executive committee, and the board's secretary, will retire in March 2020 after 35 years at the company. Claudia Böckstiegel, who is currently the head of legal of Roche's diagnostics division, will take over as general counsel. On April 1, 2020, she will also become a member of the Enlarged Corporate Executive committee. Annette Luther, the current general manager of Roche Diagnostics International, will be the new secretary to the board. 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.